Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation

BACKGROUND: XPO1 mediates the nuclear export of several proteins, mainly tumor suppressors. KPT‐330 (Selinexor) is a selective inhibitor of XPO1 that has demonstrated good therapeutic effects in hematologic cancers. METHODS: We used TCGA and GTEx pan‐cancer database to evaluate XPO1 mRNA expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Cheng, Ma, Ben, Yang, Zi‐yi, Li, Ou, Liu, Shi‐lei, Pan, Li‐jia, Gong, Wei, Dong, Ping, Shu, Yi‐jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028126/
https://www.ncbi.nlm.nih.gov/pubmed/36200270
http://dx.doi.org/10.1002/cam4.5322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028126/
https://www.ncbi.nlm.nih.gov/pubmed/36200270
http://dx.doi.org/10.1002/cam4.5322

Ejemplares similares